Skip to main content

Table 1 Patient characteristics

From: Does high-density lipoprotein influence the development of saphenous vein graft disease after coronary bypass surgery?: exploratory analysis from the CASCADE trial

 

N = 113

Characteristic

 

  Age, years

66.5 ± 7.6

  Male gender

101 (89.4%)

  Body-mass index, kg/m2

28.4 ± 3.9

  Diabetes mellitus

33 (29.2%)

  Current smoker

15 (13.3%)

  Hypertension

88 (77.9%)

  Hyperlipidemia

99 (87.6%)

  Acute coronary syndrome*

21 (18.6%)

  Heart failure NYHA class 3-4

23 (20.4%)

Preoperative laboratory values

 

  Baseline high-density lipoprotein, mg/dL

38.4 ± 11.2

  Baseline low-density lipoprotein, mg/dL

72.8 ± 30.0

  Baseline creatinine, μmol/L

89.0 ± 17.5

Preoperative medication use

 

  Aspirin

104 (92.0%)

  Clopidogrel

12 (10.6%)

  Statin

101 (89.4%)

  Beta-blocker

87 (77.0%)

  Angiotensin converting enzyme

 

  Inhibitor

57 (50.4%)

Postoperative medication use (at discharge)

 

  Aspirin

113 (100%)

  Clopidogrel

56 (49.6%)

  Statin

103 (91.2%)

  Beta-blocker

105 (92.9%)

  Angiotensin converting enzyme

 

  Inhibitor

40 (35.4%)

Operative details

 

  Number of distal anastomoses

3.5 ± 0.7

  Left internal thoracic graft

112 (99.1%)

  Right internal thoracic graft

22 (19.5%)

  Cross-clamp time, min

64.5 ± 20.1

  Cardiopulmonary bypass time, min

90.1 ± 24.6

  Off-pump surgery

4 (3.5%)

Length of stay

 

  Duration in intensive care, days

1.4 ± 1.0

  Duration in hospital, days

8.7 ± 5.8

  1. NYHA New York Heart Association.
  2. *Recent acute coronary syndrome within 1 month.